These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 9295513)

  • 21. Amsacrine and 5-azacytidine in acute non lymphatic leukaemia (ANLL).
    Carella AM; Santini G; Marmont AM
    Haematologica; 1982 Oct; 67(5):811-2. PubMed ID: 6184273
    [No Abstract]   [Full Text] [Related]  

  • 22. Comparison of the pharmacokinetics of AMSA and AMSA-lactate in patients with acute nonlymphoblastic leukemia.
    Paul CY; Liliemark JO; Farmen RH; Franks CR; Uytdenhoef M; Peterson CO
    Ther Drug Monit; 1987 Sep; 9(3):263-71. PubMed ID: 3672568
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [The work of the nurse in administering cytostatics to the leukemic child].
    Espino Pestana D; Reyes Tolentino M; Alonso Pardo ME
    Rev Cubana Enferm; 1992; 8(2):111-8. PubMed ID: 1342742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute myocardial necrosis during administration of amsacrine.
    Lindpaintner K; Lindpaintner LS; Wentworth M; Burns CP
    Cancer; 1986 Apr; 57(7):1284-6. PubMed ID: 3753891
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Studies on programmed cell death induced by amsacrine and expression of bcl-2 in leukemia cell lines].
    Wan Y; Wu D
    Zhonghua Zhong Liu Za Zhi; 1997 Sep; 19(5):346-9. PubMed ID: 10920913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase II trial of amsacrine in patients with multiple myeloma.
    Greipp PR; Coleman M; Anderson K; McIntyre OR
    Med Pediatr Oncol; 1989; 17(1):76-8. PubMed ID: 2913481
    [TBL] [Abstract][Full Text] [Related]  

  • 28. More efficient mobilisation of peripheral blood stem cells with HiDAC+AMSA+G-CSF than with mini-ICE+G-CSF in patients with AML.
    Höglund M; Brune M; Sallerfors B; Ahlgren T; Billström R; Hedenus M; Markevärn B; Nilsson B; Simonsson B; Stockelberg D; Wahlin A
    Bone Marrow Transplant; 2003 Dec; 32(12):1119-24. PubMed ID: 14647265
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AMSA-induced seizures in patients with hypokalemia.
    Mittelman A; Arlin ZA
    Cancer Treat Rep; 1983 Jan; 67(1):102-3. PubMed ID: 6688555
    [No Abstract]   [Full Text] [Related]  

  • 31. Absence of topoisomerase IIbeta in an amsacrine-resistant human leukemia cell line with mutant topoisomerase IIalpha.
    Herzog CE; Holmes KA; Tuschong LM; Ganapathi R; Zwelling LA
    Cancer Res; 1998 Dec; 58(23):5298-300. PubMed ID: 9850052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Maintenance therapy in childhood acute myeloid leukemia.
    Perel Y; Auvrignon A; Leblanc T; Michel G; Vannier JP; Dalle JH; Gandemer V; Schmitt C; Mèchinaud F; Lamagnere JP; Piguet Ch; Couillaud G; Pautard B; Baruchel A; Leverger G; ;
    Ann Hematol; 2004; 83 Suppl 1():S116-9. PubMed ID: 15124700
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Allergic reaction following administration of AMSA.
    Rosenfelt FP; Rosenbloom BE; Weinstein IM
    Cancer Treat Rep; 1982 Mar; 66(3):594-5. PubMed ID: 6460556
    [No Abstract]   [Full Text] [Related]  

  • 34. [Feasibility of peripheral vein during FOLFOX/FOLFIRI chemotherapy through peripheral venous system].
    Kimura T; Iwase K; Aono T; Nakai S; Fujii M; Nishikawa K; Matsuda C; Shimada K; Hirota M; Nasu S; Wada D; Hasegawa J; Tanaka Y
    Gan To Kagaku Ryoho; 2008 Nov; 35(11):1889-94. PubMed ID: 19011337
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.
    Arlin Z; Mehta R; Feldman E; Sullivan P; Pucillo A
    Cancer Chemother Pharmacol; 1987; 19(2):163-4. PubMed ID: 3568274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Surveillance of the serum Candida antigen titer for initiation of antifungal therapy after post-remission chemotherapy in patients with acute leukemia.
    Iwasaki H; Misaki H; Nakamura T; Ueda T
    Int J Hematol; 2000 Apr; 71(3):266-72. PubMed ID: 10846834
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Symptomatic venous thromboembolism in acute leukemia. Incidence, risk factors, and impact on prognosis.
    Ziegler S; Sperr WR; Knöbl P; Lehr S; Weltermann A; Jäger U; Valent P; Lechner K
    Thromb Res; 2005; 115(1-2):59-64. PubMed ID: 15567454
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How I treat acute and chronic leukemia in pregnancy.
    Shapira T; Pereg D; Lishner M
    Blood Rev; 2008 Sep; 22(5):247-59. PubMed ID: 18472198
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of advanced adult acute leukemia with diglycoaldehyde: a Southwest Oncology Group study.
    Shaw MT; Morrison FS; Stuckey WJ; Trowbridge AA
    Cancer Treat Rep; 1980; 64(8-9):985-8. PubMed ID: 7004636
    [No Abstract]   [Full Text] [Related]  

  • 40. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
    Finlay GJ; Atwell GJ; Baguley BC
    Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.